Bharat Biotech's Covaxin is said to have shown 77.8 % efficacy in phase 3 trial data in review by Subject Expert Committee under the drug regulator, sources told ANI on Tuesday.
According to the data submitted, Covaxin has shown efficacy of 77.8% from the trial conducted on 25,800 subjects, according to a news report
The meeting took place before Bharat Biotech's 'pre-submission' meeting on Wednesday with the World Health Organization (WHO), for the approval for their Covid vaccine.